Doxorubicin is considered front-line therapy for “triple-negative” breast cancers (ER−, PR−, Her-2−; e.g. BT-549) [2]; however, doxorubicin is not used to treat melanoma due to intrinsic resistance. This evidence concerns the gene ERBB2 and melanoma.